Copy Link Print Information

Talabostat

(別名: Val-boroPro; PT100)
43 Cited Publications
カスタマーレビュー

Based on 43 publication(s) in Google Scholar

Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Talabostat mesylate) that retains the same biological activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度 : 95.20%
  • CAS 番号: 149682-77-9
  • 分子式: C9H19BN2O3
  • 分子量:214.07
  • 保管条件:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Talabostat Chemical Structure
    Talabostat 構造式
  • Experimental Validation Results for Talabostat
  • Experimental Validation Results for Talabostat
  • Experimental Validation Results for Talabostat
  • Experimental Validation Results for Talabostat
  • Experimental Validation Results for Talabostat
  • Experimental Validation Results for Talabostat
CAS 番号: 149682-77-9
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Talabostat:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 Talabostat

More
Customer Validation & Images
In Vivo Efficacy StudyWBCell Imaging/StainingELISA
  • ELISA
  • In Vivo Efficacy Study
  • ELISA
  • WB
  • WB
  • Cell Imaging/Staining

Dipeptidyl Peptidase アイソフォーム固有の製品をすべて表示

More

Keywords

MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Talabostat Chemical Structure
    Talabostat Chemical Structure
    1/16
  • 1/16

    Talabostat purchased from MedChemExpress. Usage Cited in: Cell. 2024 Feb 29;187(5):1223-1237.e16. [Abstract]

    Customer Validation
     Activation of CARD8 inflammasome by HIV-1 in THP-1 cells. CARD8-KO THP-1 cells expressing wild-type or mutant CARD8 were exposed to HIV reporter virus NL4-3-ΔEnv-EGFP pseudotyped with the VSVG envelope for six hours before LDH. Talabostat mesylate (VbP, 5 μM) was used as a positive control, as it induces cell death and IL-1β secretion.

  • 1/16

    Talabostat purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 May;44(5):554-575. [Abstract]

    Customer Validation
     Talabostat mesylate (20 µg/mouse; i.g.; once daily for 21 days) effectively inhibited tumor growth in BALB/c mice bearing 4T1 cells.

  • 1/16

    Talabostat purchased from MedChemExpress. Usage Cited in: Cell. 2023 May 11;186(10):2144-2159.e22. [Abstract]

    Customer Validation
     LDH release and IL-1b secretion by ELISA in cell-free supernatants of N/TERT-1 stably expressing mCitrine (control) or bat/human ASC2-mCitrine, treated with Talabostat mesylate (2-200 μM) for 24 h.

  • 1/16

    Talabostat purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2018 Dec 7;293(49):18864-18878. [Abstract]

    Customer Validation
     Lack of evidence for directly binding to NLRP1 by Talabostat. 293T-ASC-GFPNLRP1 cells are treated with 2 μM Talabostat for 16 hours and lysed by 3 rounds of freezing and thawing. 20 μL (2 μg/uL) clarified lysates are heated at a temperature gradient for 10 minutes, centrifuged at 16,000g for 10mins at room temperature.

  • 1/16

    Talabostat purchased from MedChemExpress. Usage Cited in: Cancer Res. 2016 Jul 15;76(14):4124-35. [Abstract]

    Customer Validation
     RAW264.7 cells of the indicated genotypes were treated with 4 µM Talabostat mesylate (Val-boroPro) for the indicated times (6-12 h). Cleaved caspase-3 in the cells was detected by Western blotting. The results indicate that Talabostat mesylate can activate caspase‑3 in Gsdmd‑knockout cells.

  • 1/16

    Talabostat purchased from MedChemExpress. Usage Cited in: Cancer Res. 2016 Jul 15;76(14):4124-35. [Abstract]

    Customer Validation
     RAW264.7 cells of the indicated genotypes were treated with 4 µM Talabostat mesylate (Val-boroPro) for the indicated times (6-12 h). Microscopic images of the cells. The results showed that Talabostat mesylate induced apoptotic morphological changes in Gsdmd‑knockout cells.

  • Talabostat